TIGECYCLINE Drug Patent Profile

Which patents cover Tigecycline, and what generic alternatives are available?

Tigecycline is a drug marketed by Accord Hlthcare Inc, Amneal, Apotex, Eugia Pharma, Fresenius Kabi Usa, Meitheal, Sandoz, and Xellia Pharms Aps. and is included in eight NDAs. There is one patent protecting this drug.

This drug has eight patent family members in eight countries.

The generic ingredient in TIGECYCLINE is tigecycline. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the tigecycline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tigecycline

A generic version of TIGECYCLINE was approved as tigecycline by SANDOZ on May 27^th, 2015.

Summary for TIGECYCLINE

International Patents:	8
US Patents:	1
Applicants:	8
NDAs:	8
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TIGECYCLINE

US Patents and Regulatory Information for TIGECYCLINE

TIGECYCLINE is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare Inc	TIGECYCLINE	tigecycline	POWDER;INTRAVENOUS	208744-001	Jan 18, 2018		DISCN	No	No
Sandoz	TIGECYCLINE	tigecycline	POWDER;INTRAVENOUS	091620-001	May 27, 2015	AP	RX	No	No
Eugia Pharma	TIGECYCLINE	tigecycline	POWDER;INTRAVENOUS	206335-001	Jun 11, 2019	AP	RX	No	No

International Patents for TIGECYCLINE

See the table below for patents covering TIGECYCLINE around the world.

Country	Patent Number	Title	Estimated Expiration
China	103315947	Tigecycline composition for injection
Poland	2881109
World Intellectual Property Organization (WIPO)	2013139179

Supplementary Protection Certificates for TIGECYCLINE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0536515	SPC/GB06/033	United Kingdom		PRODUCT NAME: TIGECYCLINE
0536515	06C0031	France		PRODUCT NAME: TIGECYCLINE; REGISTRATION NO/DATE: EU/01/06/336/001 20060424
0536515	2006/030	Ireland		PRODUCT NAME: TIGECYCLINE OR A PHARMACOLOGICALLY ACCEPTABLE ORGANIC OR INORGANIC SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/06/336/001 20060424

Investment Scenario, Market Dynamics, and Financial Trajectory for Tigecycline

Last updated: February 3, 2026

Summary

Tigecycline, marketed as Tygacil, is a broad-spectrum glycylcycline antibiotic indicated for complicated skin and soft tissue infections, intra-abdominal infections, and community-acquired pneumonia. Approved by the FDA in 2005, its market trajectory is influenced by factors such as antimicrobial resistance trends, evolving treatment guidelines, regulatory challenges, and competitive dynamics. While tigecycline has carved a niche in managing multi-drug resistant bacterial infections, its long-term market potential faces headwinds from emerging alternatives and concerns over safety profiles.

This analysis evaluates the investment potential, current market environment, and financial prospects of tigecycline, supported by data, competitor landscape, and policy considerations.

---

1. Current Market Landscape for Tigecycline

1.1. Regulatory Status and Patents

Aspect	Details
FDA Approval Year	2005
Patent Status	Patent expired in 2014 in the US; limited patent life remaining in other jurisdictions.
Orphan Drug Designation	Not granted; limited exclusivity extensions.

1.2. Indications and Usage

• Approved Indications:

  • Complicated intra-abdominal infections (cIAI)
  • Complicated skin and skin structure infections (cSSSI)
  • Community-acquired bacterial pneumonia (CABP)

• Off-label Use: Often in multi-drug resistant infections, particularly in hospital settings.

1.3. Market Penetration

Region	Market Share (Estimated, 2022)	Key Usage Drivers
North America	45%	High resistance rates, hospital protocols
Europe	30%	Steady usage, limited by approval scope
Rest of World	25%	Limited due to regulatory and pricing constraints

---

2. Market Dynamics Influencing Tigecycline

2.1. Antimicrobial Resistance Trends

• Rising prevalence of multi-drug resistant organisms (MDROs), including carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa, and Acinetobacter baumannii, sustain demand.
• Tigecycline’s Role: Due to activity against resistant strains, tigecycline is often a last-resort antibiotic in combatting severe infections.

2.2. Competition Landscape

Competitor/Alternatives	Market Position	Strengths	Limitations
Carbapenems (e.g., Meropenem, Imipenem)	First-line for resistant infections	Broad-spectrum activity	Resistance emerging
Polymyxins (e.g., Colistin)	Last-resort for MDR Gram-negatives	Activity against CRE, Pseudomonas	Toxicity issues, limited spectrum
Other Glycylcyclines (e.g., Omadacycline)	Emerging agents	Efficacy against certain resistant strains	Limited data, newer entrant

• Market Share Estimate (2022):
  • Tigecycline: ~12%
  • Competing antibiotics: balance of remaining share

2.3. Clinical and Regulatory Challenges

• Adverse Safety Profile: Noted for nausea, vomiting, and rare cases of hepatotoxicity, impacting physician preference.
• Limited Efficacy Data: Some clinical trials show modest benefits; resistance development remains a concern.
• Regulatory Scrutiny: Concerns over mortality risk noted during FDA review, affecting labels and prescribing practices.

2.4. Pricing and Reimbursement

Market	Average Price per Vial (USD)	Reimbursement Environment
US	$200–$300	Generally reimbursed, but constraints exist
Europe	€150–€250	Varies by country; some restrict use
Rest of World	Varies	Limited due to pricing policies

Pricing pressures and reimbursement policies significantly influence revenue trajectories.

---

3. Financial Trajectory and Investment Outlook

3.1. Revenue Projections (2023–2030)

Year	Estimated Global Revenue (USD Millions)	Assumptions
2023	$250–$300	Stabilization after patent expiry; moderate growth
2025	$300–$400	Increased adoption in resistant infections; new formulary guidelines
2027	$350–$500	Competition intensifies; potential emergence of biosimilars
2030	$400–$600	Growth driven by resistant infection management needs

3.2. Key Financial Drivers

• Market Penetration: growth in hospital and ICU settings managing resistant infections.
• Pricing Trends: potential discounts due to biosimilar entries and payor negotiations.
• Regulatory Developments: approvals for new indications or formulations could boost sales.

3.3. Investment Risks

Risk Factor	Impact	Mitigation Strategies
Resistance Development	Limits efficacy, reduces market size	Monitoring resistance trends, combination therapies
Safety and Efficacy Concerns	Regulatory scrutiny, preference decline	Post-marketing studies, safety updates
Patent Expiry and Competition	Market erosion, biosimilar entry	Diversification into new formulations or indications
Pricing and Reimbursement**	Reduced revenue potential	Engage with payors early, tiered pricing strategies

3.4. Strategies to Enhance Portfolio Value

Strategy	Expected Impact
Development of Next-Gen Derivatives	Overcoming resistance, expanding indications
Expansion into Emerging Markets	Higher volume sales, new revenue streams
Combination Therapy R&D	Improved efficacy, reduced resistance development
Regulatory Engagement for New Indications	Market expansion, higher revenue potential

---

4. Comparative Analysis: Investment in Tigecycline vs. Alternatives

Aspect	Tigecycline	Alternatives (e.g., Carbapenems, Polymyxins)
Resistance Profile	Broad against resistant strains	Resistance emerging in some areas
Safety Profile	Moderate; nausea/vomiting, rare hepatotoxicity	Variable; polymyxins associated with nephrotoxicity
Pricing	Moderate to high, sensitive to biosimilar entry	Typically similar or lower for generics
Regulatory Environment	Stable but cautious (due to safety concerns)	Well-established, with evolving restrictions
Market Penetration	Niche, last-resort positioning	Widely used, first-line in many settings

---

5. Policy and Industry Trends Impacting Market

• Global Antimicrobial Stewardship: Increasing efforts to curb overuse may limit growth.
• Regulatory Flexibility: Accelerated approvals for novel agents could threaten tigecycline's niche.
• Public Health Initiatives: Focus on reducing antimicrobial resistance could both increase demand for last-line agents and impose stricter usage guidelines.
• Patent Expiries: Reduced exclusivity lowers prices and margins; necessitates pipeline diversification.

---

6. Deep Dive: Comparative Performance Data (2022)

Parameter	Tigecycline	Meropenem	Colistin	Omadacycline
Market Share	12%	35%	10%	3%
Resistance Coverage	MDR, XDR bacteria	Broad-spectrum	CRE, MDR	Similar spectrum, newer agent
Adverse Events Rate (%)	15% nausea, 2% hepatotoxicity	5% GI, 1% seizures	20% nephrotoxicity	Limited data
Cost per Treatment Course (USD)	$2000–$5000	$1500–$2000	$1000–$3000	Varies

---

7. Key Considerations for Investors

• Market Growth Drivers:
  • Rising MDRO prevalence
  • Increasing hospital budgets for resistant infection management
• Market Limiters:
  • Safety concerns
  • Patents and biosimilar emergence
  • Regulatory scrutiny
• Growth Opportunities:
  • Entry into emerging markets
  • Development of combination regimens
  • Diagnostics support for targeted therapy

---

Key Takeaways

• Tigecycline remains a critical agent for resistant bacterial infections, with a stable, though gradually declining, market share.
• Market growth hinges on antimicrobial resistance trends and improving safety profiles through clinical innovation.
• Patent expiration and biosimilar competition will likely lead to reduced margins, emphasizing the need for pipeline diversification.
• Regional disparities in adoption and reimbursement strategies should guide strategic expansion.
• Clinical and regulatory challenges are paramount; investments in post-marketing surveillance and next-generation agents could offset declining exclusivity benefits.

---

Frequently Asked Questions (FAQs)

1. What factors are driving the current demand for tigecycline?

Rising antimicrobial resistance, especially among multi-drug resistant Gram-negative bacteria, sustains demand for tigecycline as a critical reserve antibiotic in hospital settings.

2. How does resistance development impact the long-term viability of tigecycline?

Increasing resistance could diminish effectiveness, leading to reduced market share. Continuous surveillance and development of combination therapies are vital to prolong its utility.

3. What are the main regulatory concerns associated with tigecycline?

The primary concern involves safety profiles—particularly adverse events like nausea, vomiting, and hepatotoxicity—which influence prescribing patterns and regulatory labels.

4. How do biosimilars and generics influence tigecycline's market?

Biosimilar and generic entries lower prices, eroding margins and market exclusivity, especially post patent expiry, thus necessitating strategic innovation.

5. What are the prospects for new formulations or indications for tigecycline?

Potential exists, especially if clinical trials demonstrate efficacy in additional resistant or difficult-to-treat infections, supported by regulatory pathways for new indications.

---

References

1. U.S. Food and Drug Administration (FDA). Tygacil (Tigecycline) Prescribing Information. 2005.
2. World Health Organization. Global antimicrobial resistance surveillance system (GLASS). 2022.
3. MarketsandMarkets. Antibiotics Market by Type, Application, and Region—Forecast to 2027.
4. European Medicines Agency (EMA). Assessment reports for antibiotics.
5. Industry Reports. (2022). "Antibiotics Market Analysis and Forecast," GlobalData.

---

This comprehensive analysis provides actionable insights for investors, pharmaceutical developers, and healthcare stakeholders assessing tigecycline's market potential and financial trajectory.